CRISPR Therapeutics' CMO Naimish Patel Granted Stock Options for 18,333 Shares

The granted options vest over four years, aligning Patel’s compensation with the company's long-term goals.

October 23, 2024

Naimish Patel Receives Stock Options from CRISPR Therapeutics

Naimish Patel, Chief Medical Officer of CRISPR Therapeutics AG, has been awarded stock options for 18,333 common shares of the company, according to a recent SEC filing. These options were granted on October 16, 2024, and are set at an exercise price of $49 per share. The options will vest in equal monthly installments over four years, beginning on November 16, 2024, ensuring that the long-term compensation aligns with Patel's tenure at the company.

CRISPR Therapeutics, a leader in gene-editing technologies, continues to reward its executive team with equity compensation, tying leadership incentives to the success of the company’s groundbreaking scientific advancements. Patel’s option grant further demonstrates the company's commitment to retaining key executives through competitive long-term incentives.

Vesting and Expiration

The options will vest in 48 monthly installments, meaning Patel will gradually gain ownership over the course of his service at CRISPR Therapeutics. The options have an expiration date of October 16, 2034, giving Patel a decade to exercise them, providing flexibility in capitalizing on the company’s future performance.

Aligning Executive Compensation with Company Performance

Equity-based compensation such as stock options is a standard practice in the biotech industry, particularly for companies like CRISPR Therapeutics, which rely heavily on innovation and long-term project development. These stock options not only align Patel’s interests with the company’s financial performance but also ensure that leadership remains focused on delivering value to shareholders and driving the company’s scientific and business objectives forward.

As CRISPR Therapeutics continues to pioneer advancements in gene-editing technology, the company’s leadership team, including Patel, will play a critical role in shaping its future success.